Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Matthew Holderfield, Bianca J. Lee, Jingjing Jiang, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 919-926
Open Access | Times Cited: 90

Showing 1-25 of 90 citing articles:

Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Urszula N. Wasko, Jingjing Jiang, Tanner C. Dalton, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 927-936
Open Access | Times Cited: 55
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Jeffrey A. Klomp, Jennifer E. Klomp, Clint A. Stalnecker, et al.
Science (2024) Vol. 384, Iss. 6700
Open Access | Times Cited: 30
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer
Jennifer E. Klomp, J. Nathaniel Diehl, Jeffrey A. Klomp, et al.
Science (2024) Vol. 384, Iss. 6700
Open Access | Times Cited: 20
Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Molecular principles underlying aggressive cancers
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Decoding the functional impact of the cancer genome through protein–protein interactions
Haian Fu, Xiulei Mo, Andrei A. Ivanov
Nature reviews. Cancer (2025)
Closed Access | Times Cited: 2
Recent Advances in Peptide Inhibitors Targeting Wild-Type Ras Protein Interactions in Cancer Therapy
Weirong Qin, Zijian Liu, Mingyu Huang, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1425-1425
Open Access | Times Cited: 2
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
Marie‐Julie Nokin, Alessia Mira, Enrico Patrucco, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 11
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer
Haniel A. Araújo, Ximo Pechuan-Jorge, Teng Zhou, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2183-2208
Closed Access | Times Cited: 10
The Missing Link(er): A Roadmap to Macrocyclization in Drug Discovery
Christian Brudy, Carlo Walz, Moritz Spiske, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 17, pp. 14768-14785
Closed Access | Times Cited: 8
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
Junya Sango, Saul Carcamo, Maria Sirenko, et al.
Nature (2024) Vol. 636, Iss. 8041, pp. 241-250
Open Access | Times Cited: 8
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
Yuankai Shi, Jian Fang, Ligang Xing, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 1
Discovery of fully synthetic FKBP12-mTOR molecular glues
Robin C. E. Deutscher, Christian Meyners, Maximilian Repity, et al.
Chemical Science (2025) Vol. 16, Iss. 10, pp. 4256-4263
Open Access | Times Cited: 1
Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Syeda A. Mina, Mohamed Shanshal, Konstantinos Leventakos, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 353-353
Open Access | Times Cited: 1
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
Jakob M. Riedl, Ferran Fece de la Cruz, W. Marston Linehan, et al.
Annals of Oncology (2025)
Open Access | Times Cited: 1
Identification and characterization of ternary complexes consisting of FKBP12, MAPRE1 and macrocyclic molecular glues
Michael Salcius, Antonin Tutter, Marianne Fouché, et al.
RSC Chemical Biology (2025)
Open Access | Times Cited: 1
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Szu-Aun Long, Amber M. Amparo, Grace Goodhart, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance
Jameela Lokhandwala, Tracess Smalley, Timothy H. Tran
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy
Laura D'Alessio‐Sands, Joshua Gaynier, Victoria Michel‐Milian, et al.
Drug Development Research (2025) Vol. 86, Iss. 1
Closed Access
KRAS Oncoprotein Signaling in Cancer
Piro Lito
New England Journal of Medicine (2025) Vol. 392, Iss. 3, pp. 296-298
Closed Access
Oncogenic mutant KRAS inhibition through oxidation at cysteine 118
Maximilian Kramer‐Drauberg, Ettore Petrini, Alessia Mira, et al.
Molecular Oncology (2025)
Open Access
Page 1 - Next Page

Scroll to top